<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02114307</url>
  </required_header>
  <id_info>
    <org_study_id>13HH0768</org_study_id>
    <nct_id>NCT02114307</nct_id>
  </id_info>
  <brief_title>REVITIVE for the Treatment of Patients With Venous Insufficiency</brief_title>
  <acronym>RVI</acronym>
  <official_title>REVITIVE for the Treatment of Patients With Venous Insufficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Actegy Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the efficacy of an electrical stimulation (using the REVITIVE IX device) in
      treating patients with venous insufficiency.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot randomised control trial to assess the efficacy of a neuromuscular electrical
      stimulation device to improve venous blood flow and patients' symptoms in patients with
      chronic venous insufficiency. The Revitive IX device is a neuromuscular electrical
      stimulation device that gives wide pulse pattern electrical stimulation via foot pads. A
      cycle of treatment consists of a 30 minute programme of 15 varying waveforms that last a
      minute each.

      Twenty patients with venous insufficiency will be screened according the eligibility
      criteria. Patients will be randomised to either treatment or control (sham device) group.
      Patients are advised to use the device 30 minutes a day, everyday, for 6 weeks. Compliance
      will be monitored with a data logger and diary card.

      Primary outcome measure:

      a) improvement in venous haemodynamics.

      Secondary outcome measures:

        1. improvement in lower limb oedema

        2. improvement in clinical symptoms

        3. reduction in lower limb pain and discomfort

        4. improvement in quality of life measures

        5. device satisfaction.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2014</start_date>
  <completion_date type="Actual">October 1, 2014</completion_date>
  <primary_completion_date type="Actual">October 1, 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Venous Haemodynamics - Percent Change in Time Averaged Mean Velocity TAMV</measure>
    <time_frame>0 and 6 weeks</time_frame>
    <description>Femoral vein haemodynamics is measured using ultrasound scan - Time Averaged Mean Velocity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Limb Swelling, Volume</measure>
    <time_frame>0 and 6 weeks</time_frame>
    <description>Lower limb oedema measured before and after using the device at 0 and 6 weeks using a perimeter.
Limb volume was measured using an optoelectronic limb volumeter. Patients using compression stockings were advised to remove stockings 2 h prior to their appointment. Measurements were taken with the patient seated and the affected leg in a horizontal position. Five readings were taken before and after device usage at Week 0 and Week 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Symptoms</measure>
    <time_frame>0 and 6 weeks</time_frame>
    <description>Change in clinical symptoms as assessed by the Venous Clinical Severity Score (VCSS) from 0 to 6 weeks, lower score means improvement. Maximum score on VCSS is 30. Minimum score is 0.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Venous Insufficiency</condition>
  <condition>Oedema</condition>
  <condition>Varicose Veins</condition>
  <arm_group>
    <arm_group_label>REVITIVE IX: actual device</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trial participants will receive the true Revitive IX device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>REVITIVE IX: sham device</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Trial participants will receive a sham device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>REVITIVE IX</intervention_name>
    <description>neuromuscular electrical stimulation device</description>
    <arm_group_label>REVITIVE IX: actual device</arm_group_label>
    <arm_group_label>REVITIVE IX: sham device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to understand the study and provide meaningful written informed consent for
             the study.

          -  Willing, able, and committed to participate in the procedures for the full length of
             the study.

          -  All ethnic groups, male or female above the age of 18 years.

          -  Diagnosis of chronic venous insufficiency (C2-C5 CEAP classified)

          -  Be of non-childbearing potential; or using adequate contraception and have a negative
             urine pregnancy test result within 24 hours if appropriate before using the device.

          -  Blood pressure currently under moderate control (&lt;160/100mmHg)

          -  No current foot ulceration.

        Exclusion Criteria:

          -  Has insufficient ability to understand the subject information sheet, consent form and
             verbal instruction.

          -  Has an unstable condition (eg psychiatric disorder, a recent history of substance
             abuse or otherwise thought to be unreliable or incapable of complying wight he
             requirements of the clinical investigational plan (CIP).

          -  Has any metal implants.

          -  Pregnant.

          -  Has a cardiac pacemaker, AICD or other implanted electrical device.

          -  Has an existing DVT.

          -  Has an acute medical condition other than chronic venous insufficiency.

          -  Has recent lower limb injury or lower back pain.

          -  Has current foot ulceration or other skin ulcers.

          -  Has cardiovascular disease.

          -  Has foot deformities.

          -  Has any disorder that, in the opinion of the investigator, might interfere with the
             conduct of the study.

          -  Has an ABPI &lt; 0.8.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alun Davies, MA DM FRCS FHEA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London and Imperial College London NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Academic Department of Vascular Surgery, Charing Cross Hospital</name>
      <address>
        <city>London</city>
        <zip>W4 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Ravikumar R, Williams KJ, Babber A, Lane TRA, Moore HM, Davies AH. Randomised Controlled Trial: Potential Benefit of a Footplate Neuromuscular Electrical Stimulation Device in Patients with Chronic Venous Disease. Eur J Vasc Endovasc Surg. 2017 Jan;53(1):114-121. doi: 10.1016/j.ejvs.2016.09.015. Epub 2016 Dec 2.</citation>
    <PMID>27919609</PMID>
  </results_reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>April 11, 2014</study_first_submitted>
  <study_first_submitted_qc>April 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2014</study_first_posted>
  <results_first_submitted>June 17, 2019</results_first_submitted>
  <results_first_submitted_qc>September 20, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 10, 2019</results_first_posted>
  <last_update_submitted>September 20, 2019</last_update_submitted>
  <last_update_submitted_qc>September 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>electrical stimulation</keyword>
  <keyword>venous insufficiency</keyword>
  <keyword>post thrombotic syndrome</keyword>
  <keyword>varicose veins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venous Insufficiency</mesh_term>
    <mesh_term>Varicose Veins</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data available on request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>12 Months after publication of main study</ipd_time_frame>
    <ipd_access_criteria>From listed authors.</ipd_access_criteria>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment from vascular outpatients clinic between 20/02/2014 - 18/09/2014.</recruitment_details>
      <pre_assignment_details>Patient stayed in the full length of the study. Chronic venous insufficiency (C2-C5 CEAP). Blood pressure &lt;160/100mmHg. No current foot ulceration</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>REVITIVE IX: Actual Device</title>
          <description>Trial participants will receive the true Revitive IX device
REVITIVE IX: neuromuscular electrical stimulation device</description>
        </group>
        <group group_id="P2">
          <title>REVITIVE IX: Sham Device</title>
          <description>Trial participants will receive a sham device
REVITIVE IX: sham device</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Test Device</title>
          <description>Patients received the REVITIVE IX device for 6 weeks of home usage.</description>
        </group>
        <group group_id="B2">
          <title>Sham Device</title>
          <description>Sham REVITIVE IX for 6 weeks of home usage.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.0" spread="12.4"/>
                    <measurement group_id="B2" value="54.6" spread="13.7"/>
                    <measurement group_id="B3" value="62.3" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Venous Haemodynamics - Percent Change in Time Averaged Mean Velocity TAMV</title>
        <description>Femoral vein haemodynamics is measured using ultrasound scan - Time Averaged Mean Velocity</description>
        <time_frame>0 and 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>REVITIVE IX: Actual Device</title>
            <description>Trial participants will receive the true Revitive IX device
REVITIVE IX: neuromuscular electrical stimulation device</description>
          </group>
          <group group_id="O2">
            <title>REVITIVE IX: Sham Device</title>
            <description>Trial participants will receive a sham device
REVITIVE IX: neuromuscular electrical stimulation device</description>
          </group>
        </group_list>
        <measure>
          <title>Venous Haemodynamics - Percent Change in Time Averaged Mean Velocity TAMV</title>
          <description>Femoral vein haemodynamics is measured using ultrasound scan - Time Averaged Mean Velocity</description>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102.4" spread="50"/>
                    <measurement group_id="O2" value="-9.1" spread="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Limb Swelling, Volume</title>
        <description>Lower limb oedema measured before and after using the device at 0 and 6 weeks using a perimeter.
Limb volume was measured using an optoelectronic limb volumeter. Patients using compression stockings were advised to remove stockings 2 h prior to their appointment. Measurements were taken with the patient seated and the affected leg in a horizontal position. Five readings were taken before and after device usage at Week 0 and Week 6</description>
        <time_frame>0 and 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Test Device</title>
            <description>Patients received the REVITIVE IX device for 6 weeks of home usage.</description>
          </group>
          <group group_id="O2">
            <title>Sham Device</title>
            <description>Sham REVITIVE IX for 6 weeks of home usage.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Limb Swelling, Volume</title>
          <description>Lower limb oedema measured before and after using the device at 0 and 6 weeks using a perimeter.
Limb volume was measured using an optoelectronic limb volumeter. Patients using compression stockings were advised to remove stockings 2 h prior to their appointment. Measurements were taken with the patient seated and the affected leg in a horizontal position. Five readings were taken before and after device usage at Week 0 and Week 6</description>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 0 prestimulation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5377" spread="1122"/>
                    <measurement group_id="O2" value="5107" spread="1252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 0 poststimulation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5422" spread="1127"/>
                    <measurement group_id="O2" value="5208" spread="1252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 6 prestimulation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5500" spread="1173"/>
                    <measurement group_id="O2" value="5143" spread="1269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 6 post stimulation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5553" spread="1168"/>
                    <measurement group_id="O2" value="5203" spread="1272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Sham Group - 6 week Time Point - Pre-stimulation versus Post-Stimulation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0023</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Test Group - 6 week Time Point - Pre-stimulation versus Post-Stimulation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0815</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Symptoms</title>
        <description>Change in clinical symptoms as assessed by the Venous Clinical Severity Score (VCSS) from 0 to 6 weeks, lower score means improvement. Maximum score on VCSS is 30. Minimum score is 0.</description>
        <time_frame>0 and 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>REVITIVE IX: Actual Device</title>
            <description>Trial participants will receive the true Revitive IX device
REVITIVE IX: neuromuscular electrical stimulation device</description>
          </group>
          <group group_id="O2">
            <title>REVITIVE IX: Sham Device</title>
            <description>Trial participants will receive a sham device
REVITIVE IX: neuromuscular electrical stimulation device</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Symptoms</title>
          <description>Change in clinical symptoms as assessed by the Venous Clinical Severity Score (VCSS) from 0 to 6 weeks, lower score means improvement. Maximum score on VCSS is 30. Minimum score is 0.</description>
          <units>Percentage change in VCSS score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.8" spread="31.2"/>
                    <measurement group_id="O2" value="6.4" spread="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.127</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>REVITIVE IX: Actual Device</title>
          <description>Trial participants will receive the true Revitive IX device
REVITIVE IX: neuromuscular electrical stimulation device</description>
        </group>
        <group group_id="E2">
          <title>REVITIVE IX: Sham Device</title>
          <description>Trial participants will receive a sham device
REVITIVE IX: sham device</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Tristan Lane</name_or_title>
      <organization>Imperial College London</organization>
      <phone>02033117317</phone>
      <email>tristan.lane@imperial.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

